Senator Calls Out Bill Ackman, Questions His Senate Hearing Comments On Drug Pricing
The Bloomberg hosts pointed out that Bill Ackman, a major Valeant shareholder and board member, has an impressive track record of investments. However, the hedge fund manager told the Senate committee that he didn't perform sufficient due diligence when it came to how the company pricing drugs.
"How believable is that to you for someone that has had such a storied career? Does that strike you as odd?" the hosts asked the Senator.
"It does strike me as very odd," the Senator answer. "I was very surprised when he said that."
The Senator added it was "very clear" that Valeant adapted a strategy of acquiring decade-old drugs of which there is no generic version and then send the prices "skyrocketing."
"It seems difficult to believe that an investor who is known to be an activist investor, not a passive investor, would not know that that is a core part of the pricing strategy of a company he has invested so heavily in," she added.
Collins also pointed out that when she, along with other members of the committee, interviewed Ackman and other Valeant stakeholders in private, they showed "no expressions of regret." However, following this week's public hearing, their attitude has now changed and are now conceding that the company's "outrageous" price hikes were not justified.
Collins concluded by stating that it is "hard to conclude anything other than pure greed being at work here."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.